GeneDx Holdings Corp.
NASDAQ Global MarketTotal Valuation
GeneDx Holdings Corp. carries a market capitalization of 2.56B, placing it among publicly traded companies globally. Its enterprise value stands at 2.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.56B |
| Enterprise Value | 2.08B |
Share Statistics
GeneDx Holdings Corp. currently has 29.80M shares outstanding.
| Shares Outstanding | 29.80M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
GeneDx Holdings Corp. trades at a trailing price-to-earnings ratio of 1,105.92. The price-to-sales ratio is 4.42, and the price-to-book ratio stands at 8.38.
| PE Ratio | 1,105.92 |
| PS Ratio | 4.42 |
| PB Ratio | 8.38 |
| P/TBV Ratio | 20.21 |
| P/FCF Ratio | -92.95 |
| P/OCF Ratio | -41.27 |
Enterprise Valuation
On an enterprise value basis, GeneDx Holdings Corp. trades at an EV/EBITDA multiple of 396.99 and an EV/FCF ratio of 349.31. The EV/Sales ratio of 4.58 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 305.93 provides insight into valuation relative to core operating earnings.
| EV / Sales | 4.58 |
| EV / EBITDA | 396.99 |
| EV / EBIT | 305.93 |
| EV / FCF | 349.31 |
Financial Position
GeneDx Holdings Corp. maintains a current ratio of 3.30, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 68.55, indicating elevated leverage, while an interest coverage ratio of -16.84 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.30 |
| Quick Ratio | 2.90 |
| Debt / Equity | 68.55 |
| Debt / EBITDA | -5.23 |
| Interest Coverage | -16.84 |
Financial Efficiency
| Return on Equity (ROE) | -40.80 |
| Return on Assets (ROA) | -22.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 9.36 |
Taxes
| Income Tax | 62,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
GeneDx Holdings Corp.'s stock has declined approximately -33.98587% over the past 52 weeks. The 50-day moving average sits at 72.71, while the 200-day moving average is 85.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -33.98587% |
| 50-Day Moving Average | 72.71 |
| 200-Day Moving Average | 85.03 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, GeneDx Holdings Corp. generated 454.43M in revenue and converted that into -106.36M in net income, yielding earnings per share of -3.63. EBITDA reached -32.03M, while operating income came in at -58.91M.
| Revenue | 454.43M |
| Gross Profit | 315.24M |
| Operating Income | -58.91M |
| Pretax Income | -106.29M |
| Net Income | -106.36M |
| EBITDA | -32.03M |
| EBIT | -58.91M |
| Earnings Per Share (EPS) | -3.63 |
Balance Sheet
GeneDx Holdings Corp. holds 132.55M in cash and equivalents against 167.40M in total debt, resulting in a net debt position of 36.52M. Total book value stands at 244.22M, with working capital of 171.73M providing operational flexibility.
| Cash & Cash Equivalents | 132.55M |
| Total Debt | 167.40M |
| Net Debt | 36.52M |
| Equity (Book Value) | 244.22M |
| Book Value Per Share | 8.19 |
| Working Capital | 171.73M |
Cash Flow
GeneDx Holdings Corp. produced -48.71M in operating cash flow over the past twelve months. After subtracting -27.09M in capital expenditures, free cash flow totaled -75.80M - equivalent to -2.59 per share.
| Operating Cash Flow | -48.71M |
| Capital Expenditures | -27.09M |
| Free Cash Flow | -75.80M |
| FCF Per Share | -2.59 |
Margins
GeneDx Holdings Corp. operates with a gross margin of 69.37, reflecting its pricing power and cost economics. The operating margin of -12.96 and net profit margin of -23.40 provide insight into operational efficiency.
| Gross Margin | 69.37 |
| Operating Margin | -12.96 |
| Pretax Margin | -23.39 |
| Profit Margin | -23.40 |
| EBITDA Margin | -7.05 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -3.60 |
| FCF Yield | -1.08 |
Stock Splits
GeneDx Holdings Corp.'s most recent stock split took place on May 4, 2023 with a 33:1 split ratio.
| Last Split Date | 5/4/2023 |
| Split Ratio | 33:1 |
Scores
GeneDx Holdings Corp. posts an Altman Z-Score of 0.53, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.53 |